Status:
RECRUITING
Diagnostic Assessment of Amino Acid PET/MRI in the Evaluation of Glioma and Brain Metastases
Lead Sponsor:
Norwegian University of Science and Technology
Collaborating Sponsors:
St. Olavs Hospital
University of Bergen
Conditions:
Brain Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
MRI is used in clinical routine for diagnosing brain tumors, but has limitations in identifying tumor grade, true tumor extension and differentiate viable tumor tissue from treatment induced changes a...
Eligibility Criteria
Inclusion
- Inclusion criteria Glioma (LGG, HGG and recurrent HGG):
- Planned treatment for WHO grade II-IV diffuse glioma
- Adult patients (\>18 years)
- Planned tissue sampling for histopathological diagnosis.
- KPS \>60 (able to care for self)
- Inclusion criteria Brain Metastasis:
- Indication of surgery or stereotactic radiosurgery for 1-4 brain metastases
- Planned surgery: Suspicion of brain metastasis or known diagnosis
- Stereotactic surgery: Known primary cancer
- Adult patients (\>18 years)
- Estimated survival at least 3 months after inclusion
Exclusion
- Exclusion criteria (Glioma and Brain Metastasis):
- Pacemakers or defibrillators not compatible with 3T MRI
- No ability to obtain informed consent (e.g. due to severe dysphasia or cognitive deficits).
- Pregnancy (pregnancy test for all women in fertile age when doubt about possible pregnancy exist)
- Breastfeeding
- Weight \> 120 kg
Key Trial Info
Start Date :
November 25 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT04111588
Start Date
November 25 2019
End Date
December 31 2027
Last Update
June 22 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Haukeland universitetssykehus
Bergen, Norway
2
Universitetssykehus Nord Norge
Tromsø, Norway
3
St Olavs Hospital
Trondheim, Norway